In:
Journal of Labelled Compounds and Radiopharmaceuticals, Wiley, Vol. 54, No. 11 ( 2011-09), p. 702-707
Abstract:
The glycine transporter type 1 (GlyT1) has emerged as a key novel target for the treatment of schizophrenia. We have recently discovered and developed [ 11 C]RO5013853 as a novel positron emission tomography tracer for GlyT1 for which a reliable five‐step synthetic route was established. The incorporation of the radioisotope was achieved in the final step through methylation of a sodium sulfinate precursor, itself easily accessible upon reduction of the corresponding sulfonyl‐chloride analog. [ 11 C]RO5013853 was prepared with high specific activity ( 〉 49 GBq/µmol) and high radiochemical purity (100%). A validation study of [ 11 C]RO5013853 in animal imaging studies is in progress. Copyright © 2011 John Wiley & Sons, Ltd.
Type of Medium:
Online Resource
ISSN:
0362-4803
,
1099-1344
Language:
English
Publisher:
Wiley
Publication Date:
2011
detail.hit.zdb_id:
1491841-9
SSG:
15,3